PRLog (Press Release)
- Apr. 4, 2012 -
Rosa & Co. LLC today announced that Dr. Birgit Schoeberl, Merrimack Pharmaceuticals will present a webinar “Using Mathematical Models To Set Design Criteria For Antibody-Based Therapies” on Tuesday, April 17, 2012 at 1:00 to 2:00 pm EST as part of Rosa’s ongoing monthly public webinar series. The purpose of the series, “Impact of Modeling & Simulation in Drug Development”
, is to foster the use of Modeling and Simulation (M&S) activities in biotechnology, pharmaceutics, and other life science industries. This series is geared to illustrate the advantages and applicability of M&S in product discovery, development, and marketing programs.
According to Dr. Schoeberl, “Monoclonal antibodies are valuable as anticancer therapeutics because of their ability to selectively bind tumor-associated target proteins like receptor tyrosine kinases. However, most tumors are dependent on more than one pathway, which implies rational antibody combinations or bispecific antibodies. In our presentation, we will illustrate the use of kinetic computational models that capture protein–protein interactions to explore antibody combinations vs. bispecific antibodies, and different formats of bispecific antibodies, to set antibody design specifications such as affinity and valence, and to predict potency.”
Register for this free webinar at www.rosaandco.com/
webinar. After registering, a confirmation email will be sent with directions for joining the webinar. More information about the webinar series, an archive of past webinars, and a list of future webinar speakers may be found at http://www.rosaandco.com/webinar
Rosa informs our customer’s most critical decisions – from preclinical through clinical development – with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/
pharmacodynamic (PK/PD) models and Rosa’s innovative PhysioPD™ models. With these approaches, Rosa’s clients collaborate in model creation and testing, retain the final model, and acquire the ability to use it and understand its implications for their drug development programs. Rosa’s staff have unparalleled professional experience in using drug-disease modeling and simulation (M&S) to accelerate drug development and have completed hundreds of engagements with dozens of clients in multiple therapeutic areas. The Rosa team is unique in their breadth and depth of disease area experience, which includes metabolic and cardiovascular diseases, oncology, gastro-intestinal disease, inflammatory diseases, immune dysfunction (including rheumatoid arthritis), pain, skin conditions, respiratory disorders, and antibacterials/
antivirals. For more information, visit http://www.rosaandco.com
Rosa and the Rosa logo are registered trademarks of Rosa & Co. LLC.
# # #
Rosa creates robust mathematical models that simulate drug effects and trial outcomes. Modeling and Simulation complement traditional experimental methods, enabling unique insights that streamline drug development and regulatory interactions.